Company > Research

Research Projects

 

 

Neurodevelopmental Challenges

A biomedical clinical study measured the nutritional status of children with autism spectrum disorders (ASD) vs. a control group of neurotypical children and found low levels of many nutrients and impaired biochemical pathways in the ASD group.  Supplementation improved neurotransmitter levels, glutathione levels, methylation, detoxification, and transsulfuration pathways, normalized plasma ATP, and reduced oxidative stress.
Click to view the Biomedical Clinical Study Overview

Inflammatory Bowel Disease

Yasoo Health Ltd was awarded a research grant from the European organization EUREKA (www.eureka.be) to support its research and development work on a product for the management and adjuvant therapy of Inflammatory Bowel Disease (IBD). IBD (which includes Crohn’s and ulcerative colitis) is a chronic inflammatory condition affecting millions of people worldwide, often exacerbated by malabsorption of important nutrients and antioxidants. The anti-inflammatory effectiveness of antioxidant / anti-inflammatory compounds is being evaluated in cell and animal models of inflammation, with human clinical studies planned. More details on the project can be found at: www.inflatreat.com.

Cancer Chemoprevention

Yasoo Health Ltd received a research grant from the Cyprus Research Promotion Foundation (www.research.org.cy) to support its research and development work on the identification and development of chemo-preventive products for the prevention and treatment of prostate and breast cancer.  Yasoo’s scientists have identified a number of lead compounds that have anti–cancer activity in in vitro cell systems.

Type 2 Diabetes

Yasoo Health Ltd was awarded a research grant from the Cyprus Research Promotion Foundation (www.research.org.cy) to support its research and development work on the development of novel, antioxidant-rich formulations for the prevention and management of type 2 diabetes and its complications. Free radicals and oxidative stress are not only implicated in the pathogenesis of diabetes but they are also responsible for causing diabetes-related complications. The research will be completed by Yasoo’s subsidiary Diabetes Research Technologies Ltd. (DRT) at the Cyprus Institute of Neurology and Genetics (www.cing.org.cy) and in collaboration with Dr Klearchos Papas, Assistant Professor at the Diabetes Institute of Immunology and Transplantation, University of Minnesota. DRT has established a novel animal model for type 2 diabetes, which is being used to evaluate the efficacy of novel antioxidant formulations in improving diabetes control and reducing the risk of diabetes complications.